Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Oct 17 2015

Volume: 386

Issue: 10003

Affiliations

[1 ] Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: d.roth@med.miami.edu.

[2 ] Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA.

[3 ] Department of Renal Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden.

[4 ] Yale University Digestive Disease, Yale New Haven Hospital Transplant Center, New Haven, CT, USA.

[5 ] Hospital Universitario Austral, Pilar, Argentina.

[6 ] Hepatology & Transplant Medicine, Houston Methodist Hospital, Houston, TX, USA.

[7 ] Division of Hepatology, University of Miami Miller School of Medicine, Miami, FL, USA.

[8 ] Unité d'Hépatologie, Hôpital Cochin; Université Paris Descartes; and UMS20, Institut Pasteur; Paris, France.

[9 ] Liver Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.

[10 ] Southern California Research Center, Coronado, CA, USA.

[11 ] Division of Hepatology, Carolinas Medical Center, Charlotte, NC, USA.

[12 ] Liver Unit, Carmel Medical Center Technion Faculty of Medicine, Haifa, Israel.

[13 ] Merck & Co, Inc, Kenilworth, NJ, USA.

Article

Publisher Item ID: S0140-6736(15)00349-9

DOI: 10.1016/S0140-6736(15)00349-9

PubMed ID: 26456905

SO-VID: f351f2ad-c1cd-42d7-bdc2-95985211fa07

History

Data availability:

Comments

Comment on this article

Cited by 185

See all cited by

- Version 1